Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xenon Feels No Pain After $41M Upfront From Teva

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.

You may also be interested in...



Teva/Xenon’s Pain Ointment Failure Leaves Sparser Nav1.7 Pipeline

Once highly anticipated as an alternative mechanism for pain, the Nav1.7 target suffered another blow with Teva/Xenon’s failure of TV-45070 in osteoarthritis, though the class may still work in neuropathic pain.

Xenon Progresses Antisense Anemia Drug In Pact With Isis

Private drug developer Xenon will move forward development of the novel anemia drug XEN701 for patients with chronic kidney disease and pay $2 million to partner Isis.

Pain Drug Development Becomes Personalized

Advances in pain neurobiology point to the promise of more specific drugs with fewer side effects, yet the field continues to show few successes. Nevertheless, fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel